Full Text
HPR41 Biosimilars: The Key to Lowering Access Barriers to Omalizumab Across Europe

Abstract

Authors

S Yi H Yoo S Park M Jang

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×